2027 Co-op Analytical & Bioanalytical Sciences
Regeneron Pharmaceuticals
Summary
Regeneron is currently seeking multiple 2027 Co-ops in Analytical & Bioanalytical Sciences to join our Analytical and Biological Mass Spectrometry (ABMS), Assay Development, and R&D Chemistry teams, which develop and apply analytical, bioanalytical, and mass spectrometry-based methods to characterize therapeutic proteins, bioconjugates, and other complex biotherapeutics.
Job description
When & where
Location: Tarrytown, NY and Hawthorne, NY. Timeframe: Our Co-op positions are full-time and onsite from January-August (Spring-Summer), May/June-December (Summer-Fall), and August-December (Fall).
What you'll do
- Develop and run liquid chromatography-mass spectrometry (LC-MS) and mass spectrometry imaging (MSI) methods to characterize therapeutic proteins, bioconjugates, and biomarkers
- Apply mass spectrometry fragmentation techniques, including collision-induced dissociation (CID) and electron-based dissociation (ExD), to characterize conjugated payloads
- Use capillary electrophoresis-mass spectrometry (CE-MS) and imaged capillary isoelectric focusing (iCIEF) to characterize protein charge variants
- Build reference databases and spectral libraries, and process and interpret mass spectrometry data to validate molecular structures
- Run high-throughput proteomics workflows using data-independent acquisition (DIA) methods and perform database searching with false discovery rate (FDR) control
- Develop and evaluate platform immunoassays, including enzyme-linked immunosorbent assay (ELISA) and western blot methods, to support preclinical and clinical bioanalytical studies
- Support the development and purification of antibody-drug conjugates (ADCs) using multiple conjugation chemistries, chromatography, and peptide mapping techniques, and compare platform performance across different bioconjugate modalities
- Document experimental procedures and results, and present findings to the broader analytical sciences team
Relevant majors
Biology, Chemistry, Biomedical/Chemical Engineering, Pharmacy
Let's find out if we're a fit
- Must be enrolled in, or accepted to, an academic program pursuing an Undergraduate or Graduate degree (and be returning to school the semester following the position or graduating after the position)
- Must be able to commit to 40 hours per week from January-August, May/June-December, or August-December
- Demonstrated leadership in areas such as campus activities, clubs, sports, current or previous work, or within the community preferred
- Cumulative GPA of 3.0 or higher preferred
Requirements
- Must be enrolled in, or accepted to, an academic program pursuing an Undergraduate or Graduate degree (and be returning to school the semester following the position or graduating after the position)
- Must be able to commit to 40 hours per week from January-August, May/June-December, or August-December
- Demonstrated leadership in areas such as campus activities, clubs, sports, current or previous work, or within the community preferred
- Cumulative GPA of 3.0 or higher preferred
Benefits
- Annual bonuses
- Incentive plans
- Equity awards
- Pension or retirement benefits
- 401(k) company match
- Health and wellness programs
- Fitness centers
- Insurance benefits
- Paid time off
- Family support benefits
Company overview
Regeneron Pharmaceuticals is a leading American biotechnology company founded in 1988 and headquartered in Tarrytown, New York. The company specializes in inventing, developing, and commercializing life-transforming medicines for people with serious diseases. Regeneron is renowned for its innovative antibody technologies and has developed several groundbreaking therapies, including EYLEA® for retinal diseases, DUPIXENT® for inflammatory conditions, and the COVID-19 antibody cocktail REGEN-COV®. The company operates with a strong focus on research and development across multiple therapeutic areas including ophthalmology, oncology, cardiovascular diseases, and rare genetic disorders. Regeneron's proprietary VelocImmune® technology platform enables the rapid generation of fully human monoclonal antibodies. With over 15,000 employees globally and annual revenues exceeding $14 billion, Regeneron has established itself as a major force in the biotechnology industry, consistently ranking among the top-performing pharmaceutical companies and maintaining a robust pipeline of investigational therapies.